Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

Kumari G. Lokugamage(The University of Texas Medical Branch at Galveston), Vineet D. Menachery(Emory University)
bioRxiv (Cold Spring Harbor Laboratory)
March 9, 2020
10.1101/2020.03.07.982264
Cited by 188

Related Papers

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
|Nature|2021|781
Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis
|bioRxiv (Cold Spring Harbor Laboratory)|2020|207
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
|PLoS Biology|2021|86
Endomembrane targeting of human OAS1 p46 augments antiviral activity
|eLife|2021|80
SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3
|Journal of Virology|2023|44